Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick R Appelbaum

Showing results (271-280 of 339) with videos related to

Pageof 34
Sort By:
Blood|May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Blood|October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionJohn M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Blood|May 10, 2007
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersChunkang Chang, Barry E Storer, Bart L Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remissionRaya Mawad, Ted A Gooley, Vicky Sandhu, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2014
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemiaBoglarka Gyurkocza, Jonathan Gutman, Eneida R Nemecek, et al.
Blood|January 31, 2013
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?Amin M Alousi, Jennifer Le-Rademacher, Rima M Saliba, et al.
Blood|August 5, 2004
Duration of immunosuppressive treatment for chronic graft-versus-host diseaseBetty L Stewart, Barry Storer, Jan Storek, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Blood|January 26, 2011
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteriaMary E D Flowers, Yoshihiro Inamoto, Paul A Carpenter, et al.
Pageof 34

Showing results (271-280 of 339) with videos related to

Sort By:
Pageof 34
Blood|May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Blood|October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionJohn M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Blood|May 10, 2007
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disordersChunkang Chang, Barry E Storer, Bart L Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remissionRaya Mawad, Ted A Gooley, Vicky Sandhu, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2014
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemiaBoglarka Gyurkocza, Jonathan Gutman, Eneida R Nemecek, et al.
Blood|January 31, 2013
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?Amin M Alousi, Jennifer Le-Rademacher, Rima M Saliba, et al.
Blood|August 5, 2004
Duration of immunosuppressive treatment for chronic graft-versus-host diseaseBetty L Stewart, Barry Storer, Jan Storek, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Blood|January 26, 2011
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteriaMary E D Flowers, Yoshihiro Inamoto, Paul A Carpenter, et al.
Pageof 34